Prevents pregnancy. ANDA 202296, held by Xiromed. Desogestrel; Ethinyl Estradiol.
As of Nov 16, 2026, ANDA 202296 (Desogestrel And Ethinyl Estradiol), held by Xiromed, was first approved by FDA on Aug 30, 2013, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Desogestrel and ethinyl estradiol tablets and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table II lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desogestrel And Ethinyl Estradiol0.15MG,N/A;0.02MG,0.01MG · tablet;oral-28 | Desogestrel; Ethinyl Estradiol | Rx |
| Jun 18, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 18, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 30, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters